2D OncoSignature™ Long-Term Assay Specifications & Readouts

Discuss your project with one of our experts

Rapidly profile your compounds or biologics of interest as single or combination therapies, in an extended assay format. Obtain high quality, actionable data to drive your drug discovery program forward.

long term assay flow 


OncoSignature™ Long-Term Assay features
  • Screen across a diverse, clinically relevant panel or a more focused, tissue-specific panel
  • Cell lines grown in vendor-recommended media
  • 10 point, 3-fold dilution for single compounds
  • 9x9 full dose response matrix for compounds in combination
  • 240 h treatment times
  • Growth Inhibition measured by ATP levels
Final data report includes
  • Growth inhibition measured by ATP levels
  • Single agent report - dose response curve, response area, max response, doubling time, IC50 & GI50
  • Combination report - dose matrix and model score (i.e., Synergy Score, Loewe Volume Score, Bliss Volume Score)
  • Chalice™ and raw data files provided
  • Chalice™ viewer software provided

    Oncosignature Long-Term Assay (LTA): cell panel screening of slower-acting therapeutics
    Oncosignature Long-Term Assay (LTA): cell panel screening of slower-acting therapeutics
    Slower acting inhibitor classes (PARP and EZH2 inhibitors) showed greater responses in the 10-day LTA (shift to right along X axis, as indicated by arrows) compared to the standard 6-day assay. In contrast, responses for a faster acting therapeutic (WEE1i) were generally similar (points distributed along X=Y line indicating equal response at 6-days and 10-days). Notably, analysis of max response for Olaparib showed that cytotoxic response (>100% growth inhibition) only became evident in the longer duration assay (lower graph).

Contact us to discuss your next project

Required fields marked with * Required

When time is crucial in developing new drugs, take advantage of the high throughput screening technologies offered in our assay services. From planning and execution to data analysis, we have the expertise to move your project forward. Contact us to discuss your project, one of the team will be in touch within 48 hours.

Cell Panel Screening services

Answer questions in biologically relevant cancer cell types Leveraging our expertise in screening and receive robust data from high-throughput assays

Long-Term Assay application note

View the data behind the long-term assay service that allows for the profiling of slow acting or epigenetic drugs for 10 days across a clinically relevant panel of 248 cell lines

Read Horizon's CPS blog

Get the latest insights about the drug discovery tools in the cancer cell panel screening field, curated by Horizon's scientists